查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947852

RNAi療法市場分析及預測（至2035年）：依類型、產品類型、技術、應用、最終使用者、製程、實施類型及功能分類

RNAi Therapeutics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Process, Deployment, Functionality
出版日期: | 出版商: Global Insight Services | 英文 336 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

RNAi療法市場預計將從2024年的26億美元成長到2034年的81億美元，複合年成長率約為10%。 RNAi療法市場涵蓋利用RNA干擾技術抑制特定基因表現的治療方法，可望實現精準醫療。這種創新方法針對遺傳性和複雜疾病，推動了藥物研發的進步。對遺傳通路更深入的了解以及生物技術領域投資的不斷增加正在推動市場成長，凸顯了個人化醫療解決方案和新型藥物遞送系統的重要性。

由於基因靜默技術的進步和治療應用範圍的不斷擴大，RNAi療法市場正經歷強勁成長。目前，腫瘤治療領域成長最為迅猛，這主要得益於對標靶癌症治療的需求以及RNAi在治療傳統上難以治療的標靶方面的巨大潛力。緊隨其後的是遺傳性疾病領域，該領域因其透過精準醫療為罕見疾病和遺傳性疾病提供解決方案的潛力而備受關注。在該領域，小干擾RNA（siRNA）療法憑藉其在臨床試驗中已證實的有效性和安全性而主導。微型RNA（miRNA）療法能夠同時調控基因表現，從而帶來廣泛的治療益處，已成為成長第二快的領域。策略聯盟和對RNAi技術平台不斷成長的投資進一步推動了市場發展，預示著該領域具有巨大的創新和擴張潛力。

市場區隔
類型 siRNA、miRNA、shRNA
產品 治療方法、試劑和耗材
科技 奈米顆粒遞送、脂質體遞送、病毒遞送
應用領域 腫瘤學、心血管疾病、神經退化性疾病、感染疾病、遺傳性疾病
最終用戶 製藥公司、生技公司、研究機構
過程 藥物發現、臨床開發、非臨床試驗
部署 體內、體外、體外
功能 基因靜默，基因調控

RNAi療法市場正經歷動態變化，策略定價和創新產品發布推動著市場佔有率的成長。各公司正利用先進的RNA干擾技術推出新型療法，以滿足尚未滿足的醫療需求。注重成本效益和治療效果是競爭優勢的關鍵。此市場環境的特點是產品平臺豐富，並呈現出向個人化醫療和標靶治療顯著發展的趨勢。合作與夥伴關係塑造了市場發展軌跡，增強了研發能力並加速了產品開發。競爭標竿分析表明，主要參與者不斷創新以保持其競爭優勢。監管影響至關重要，北美和歐洲嚴格的監管準則影響市場准入和擴大策略。法規環境促進了安全性和有效性框架的建立，從而推動了合規性和創新。市場分析強調了策略聯盟和監管合規的重要性，認為它們是實現永續成長和市場滲透的關鍵因素。

主要趨勢和促進因素：

受基因研究進展和慢性病發病率上升的推動，RNAi療法市場正經歷強勁成長。關鍵趨勢包括開發標靶治療，其精準度更高，副作用更少，優於傳統治療方法。這種精準醫療方法正日益受到重視，與個人化醫療解決方案的廣泛普及相契合。 RNA遞送系統的新興技術正在提升RNAi療法的療效和安全性。這項進步對於克服穩定性和遞送效率的傳統挑戰至關重要。隨著各國政府認知到RNAi療法在滿足未被滿足的醫療需求方面的潛力，監管支持和有利政策進一步推動了市場擴張。生物技術公司與研究機構之間的策略聯盟和夥伴關係正在促進創新並加速產品開發。此外，生物技術和製藥領域研發投入的增加為相關人員探索新的治療應用提供了沃土。人們對RNAi潛力的認知不斷提高，鼓勵更多相關人員投資於這個充滿前景的領域，為未來的突破鋪路。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • siRNA
    • 微型RNA
    • shRNA
  • 市場規模及預測：依產品分類
    • 治療藥物
    • 試劑
    • 消耗品
  • 市場規模及預測：依技術分類
    • 基於奈米顆粒的藥物遞送
    • 基於脂質的遞送
    • 病毒載體遞送
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 循環系統
    • 神經退化性疾病
    • 感染疾病
    • 遺傳性疾病
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究所
  • 市場規模及預測：依製程分類
    • 藥物發現
    • 臨床開發
    • 臨床前試驗
  • 市場規模及預測：依發展狀況
    • In vivo
    • 體外
    • Ex Vivo
  • 市場規模及預測：依功能分類
    • 基因靜默
    • 基因調控

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Silence Therapeutics
  • Dicerna Pharmaceuticals
  • Arcturus Therapeutics
  • Benitec Biopharma
  • Quark Pharmaceuticals
  • RXi Pharmaceuticals
  • Marina Biotech
  • Calando Pharmaceuticals
  • Sirnaomics
  • Genevant Sciences
  • Oli X Pharmaceuticals
  • Silenseed
  • Atalanta Therapeutics
  • Mi NA Therapeutics
  • Stemirna Therapeutics
  • Phio Pharmaceuticals
  • Sterna Biologicals
  • Gradalis

第9章：關於我們

簡介目錄
Product Code: GIS10510

RNAi Therapeutics Market is anticipated to expand from $2.6 billion in 2024 to $8.1 billion by 2034, growing at a CAGR of approximately 10%. The RNAi Therapeutics Market encompasses treatments utilizing RNA interference to silence specific gene expressions, offering potential for precision medicine. This innovative approach targets genetic disorders and complex diseases, driving advancements in drug development. Increasing understanding of genetic pathways and rising investments in biotech propel market growth, emphasizing personalized healthcare solutions and novel delivery systems.

The RNAi Therapeutics Market is experiencing robust growth, propelled by advancements in gene-silencing technologies and increasing therapeutic applications. The oncology segment is currently the top-performing sector, driven by the need for targeted cancer treatments and the promise of RNAi in addressing previously undruggable targets. Following closely is the genetic disorders segment, which is gaining traction due to its potential to provide solutions for rare and inherited diseases through precision medicine. Within these segments, small interfering RNA (siRNA) therapeutics lead, owing to their established efficacy and safety profiles in clinical trials. The microRNA (miRNA) therapeutics sub-segment is emerging as the second-highest performer, with its ability to modulate multiple gene expressions simultaneously, offering a broad therapeutic impact. The market is further bolstered by strategic collaborations and increasing investments in RNAi technology platforms, indicating a promising future for innovation and expansion in this domain.

Market Segmentation
TypesiRNA, miRNA, shRNA
ProductTherapeutics, Reagents, Consumables
TechnologyNanoparticle Delivery, Lipid-based Delivery, Viral Delivery
ApplicationOncology, Cardiovascular, Neurodegenerative Disorders, Infectious Diseases, Genetic Disorders
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes
ProcessDrug Discovery, Clinical Development, Preclinical Studies
DeploymentIn Vivo, In Vitro, Ex Vivo
FunctionalityGene Silencing, Gene Regulation

The RNAi Therapeutics Market is witnessing a dynamic shift with a growing market share attributed to strategic pricing and innovative product launches. Companies are leveraging advanced RNA interference technologies to introduce novel therapeutics, catering to unmet medical needs. The strategic emphasis on cost-effectiveness and therapeutic efficacy is driving competitive positioning. This landscape is marked by a robust pipeline of products, indicating a significant trend towards personalized medicine and targeted therapies. The market's trajectory is shaped by collaborations and partnerships that enhance research capabilities and expedite product development. Competition benchmarking reveals a landscape dominated by key players who are continuously innovating to maintain a competitive edge. Regulatory influences play a pivotal role, with stringent guidelines in North America and Europe impacting market entry and expansion strategies. The regulatory environment fosters a framework for safety and efficacy, driving compliance and innovation. The market analysis underscores the importance of strategic alliances and regulatory navigation as critical factors for sustained growth and market penetration.

Geographical Overview:

The RNAi Therapeutics Market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by substantial investments in research and development. The region's advanced healthcare infrastructure and strong focus on biotechnology innovation further bolster market expansion. Europe follows closely, with a strong emphasis on regulatory support and collaborations between academic institutions and biotech companies. The Asia Pacific region is emerging rapidly, fueled by increasing healthcare expenditure and rising prevalence of chronic diseases. Countries like China and India are becoming key players, with significant investments in RNAi research. These nations are focusing on developing cost-effective therapies to cater to their large populations. Latin America and the Middle East & Africa are gradually gaining traction in the RNAi Therapeutics Market. Brazil and South Africa are spearheading efforts in these regions, with increasing government support and growing interest from international biotech firms.

The RNAi Therapeutics Market is intricately influenced by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, escalating trade tensions necessitate strategic shifts towards enhancing domestic biotech capabilities and reducing dependency on foreign raw materials. China's focus on self-reliance is accelerating its investment in biotech innovation and localized manufacturing. Taiwan, while a pivotal player in biotech supplies, navigates geopolitical vulnerabilities amid US-China strains. Globally, the parent market exhibits robust growth, driven by advancements in genetic medicine, yet faces challenges from protectionist policies and supply chain disruptions. By 2035, market evolution will hinge on strategic alliances and supply chain resilience. Middle East conflicts further compound risks by influencing global energy prices, impacting operational costs and supply chain stability.

Key Trends and Drivers:

The RNAi therapeutics market is experiencing robust growth, driven by advancements in genetic research and the increasing prevalence of chronic diseases. Key trends include the development of targeted therapies that offer precision and reduced side effects compared to traditional treatments. This precision medicine approach is gaining traction as it aligns with the broader shift towards personalized healthcare solutions. Emerging technologies in RNA delivery systems are enhancing the efficacy and safety profiles of RNAi therapeutics. This progress is crucial for overcoming previous challenges related to stability and delivery efficiency. Regulatory support and favorable policies are further propelling market expansion, as governments recognize the potential of RNAi therapies to address unmet medical needs. Strategic collaborations and partnerships between biotech firms and research institutions are fostering innovation and accelerating product development. Additionally, the growing investment in biotechnology and pharmaceutical R&D is providing a fertile ground for market players to explore new therapeutic applications. The increasing awareness of RNAi's potential is encouraging more stakeholders to invest in this promising field, paving the way for future breakthroughs.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 siRNA
    • 4.1.2 miRNA
    • 4.1.3 shRNA
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutics
    • 4.2.2 Reagents
    • 4.2.3 Consumables
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Nanoparticle Delivery
    • 4.3.2 Lipid-based Delivery
    • 4.3.3 Viral Delivery
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Oncology
    • 4.4.2 Cardiovascular
    • 4.4.3 Neurodegenerative Disorders
    • 4.4.4 Infectious Diseases
    • 4.4.5 Genetic Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Pharmaceutical Companies
    • 4.5.2 Biotechnology Companies
    • 4.5.3 Research Institutes
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Drug Discovery
    • 4.6.2 Clinical Development
    • 4.6.3 Preclinical Studies
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 In Vivo
    • 4.7.2 In Vitro
    • 4.7.3 Ex Vivo
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Gene Silencing
    • 4.8.2 Gene Regulation

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Deployment
      • 5.2.1.8 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Deployment
      • 5.2.2.8 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Deployment
      • 5.2.3.8 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Deployment
      • 5.3.1.8 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Deployment
      • 5.3.2.8 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Deployment
      • 5.3.3.8 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Deployment
      • 5.4.1.8 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Deployment
      • 5.4.2.8 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Deployment
      • 5.4.3.8 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Deployment
      • 5.4.4.8 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Deployment
      • 5.4.5.8 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Deployment
      • 5.4.6.8 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Deployment
      • 5.4.7.8 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Deployment
      • 5.5.1.8 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Deployment
      • 5.5.2.8 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Deployment
      • 5.5.3.8 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Deployment
      • 5.5.4.8 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Deployment
      • 5.5.5.8 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Deployment
      • 5.5.6.8 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Deployment
      • 5.6.1.8 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Deployment
      • 5.6.2.8 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Deployment
      • 5.6.3.8 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Deployment
      • 5.6.4.8 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Deployment
      • 5.6.5.8 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Alnylam Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Arrowhead Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Silence Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Dicerna Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Arcturus Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Benitec Biopharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Quark Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 RXi Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Marina Biotech
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Calando Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sirnaomics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genevant Sciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Oli X Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Silenseed
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Atalanta Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Mi NA Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Stemirna Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Phio Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Sterna Biologicals
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Gradalis
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us